BRAF and metastatic melanoma: The same technology had been already investigated in metastatic melanoma patients in two previous works [13,14], reporting baseline plasma–tissue concordance for the BRAF mutation of 47% and 64.2%, respectively, whilst an overall agreement of 84% was shown in the work by Long-Mira et al. [11].